eCQM QICore Content Implementation Guide
2024.0.0 - CI Build

eCQM QICore Content Implementation Guide, published by cqframework. This guide is not an authorized publication; it is the continuous build for version 2024.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/ecqm-content-qicore-2024/ and changes regularly. See the Directory of published versions

Measure: Statin Therapy for the Prevention and Treatment of Cardiovascular DiseaseFHIR

Official URL: https://madie.cms.gov/Measure/StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Version: 0.2.000
Draft as of 2024-12-18 Responsible: Centers for Medicare & Medicaid Services (CMS) Computable Name: StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR
Other Identifiers: Short Name (use: usual, ), UUID:4d3066c5-88f7-48d2-8a93-9f946e1a41a6 (use: official, ), UUID:be1257a3-a34e-4a7b-99df-345de63365a2 (use: official, ), Publisher (use: official, )

Copyright/Legal: Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets.

CPT(R) contained in the Measure specifications is copyright 2004-2023 American Medical Association. LOINC(R) is copyright 2004-2023 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2023 International Health Terminology Standards Development Organisation. ICD-10 is copyright 2023 World Health Organization. All Rights Reserved.

Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:

  • All patients who were previously diagnosed with or currently have a diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), including an ASCVD procedure; OR
  • Patients aged 20 - 75 years who have ever had a low-density lipoprotein cholesterol (LDL-C) level >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia; OR
  • Patients aged 40 - 75 years with a diagnosis of diabetes; OR
  • Patients aged 40 - 75 with a 10-year ASCVD risk score of >= 20 percent

UNKNOWN

Title: Statin Therapy for the Prevention and Treatment of Cardiovascular DiseaseFHIR
Id: StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR
Version: 0.2.000
Url: Statin Therapy for the Prevention and Treatment of Cardiovascular DiseaseFHIR
short-name identifier:

CMS347FHIR

version-independent identifier:

urn:uuid:4d3066c5-88f7-48d2-8a93-9f946e1a41a6

version-specific identifier:

urn:uuid:be1257a3-a34e-4a7b-99df-345de63365a2

publisher (CMS) identifier:

347FHIR

Effective Period: 2025-01-01..2025-12-31
Status: draft
Publisher: Centers for Medicare & Medicaid Services (CMS)
Author: Mathematica
Description:

Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:

  • All patients who were previously diagnosed with or currently have a diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), including an ASCVD procedure; OR
  • Patients aged 20 - 75 years who have ever had a low-density lipoprotein cholesterol (LDL-C) level >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia; OR
  • Patients aged 40 - 75 years with a diagnosis of diabetes; OR
  • Patients aged 40 - 75 with a 10-year ASCVD risk score of >= 20 percent
Purpose:

UNKNOWN

Copyright:

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets.

CPT(R) contained in the Measure specifications is copyright 2004-2023 American Medical Association. LOINC(R) is copyright 2004-2023 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2023 International Health Terminology Standards Development Organisation. ICD-10 is copyright 2023 World Health Organization. All Rights Reserved.

Disclaimer:

These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].

Scoring:

Proportion

Rationale:

"Cardiovascular disease (CVD) is the leading cause of death in the United States, causing approximately 1 of every 3 deaths in the United States in 2015. In 2015, stroke caused approximately 1 of every 19 deaths in the United States and the estimated annual costs for CVD and stroke were $329.7 billion, including $199.2 billion in direct costs (hospital services, physicians and other professionals, prescribed medications, home health care, and other medical durables) and $130.5 billion in indirect costs from lost future productivity (cardiovascular and stroke premature deaths). CVD costs more than any other diagnostic group" (Benjamin et al., 2018).

Data collected between 2011 and 2014 indicates that more than 94.6 million U.S. adults, 20 years or older, had total cholesterol levels equal to 200 mg/dL or more, while almost 28.5 million had levels 240 mg/dL or more (Benjamin et al., 2018). Elevated blood cholesterol is a major risk factor for CVD and statin therapy has been associated with a reduced risk of CVD. Numerous randomized trials have demonstrated that treatment with a statin reduces LDL-C and reduces the risk of major cardiovascular events by approximately 20 percent (Ference, 2015).

In 2018, updated guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults were published (Grundy et al., 2019). This guideline was published by an Expert Panel, which synthesized evidence from randomized controlled trials to identify people most likely to benefit from cholesterol-lowering therapy. The American College of Cardiology (ACC)/American Heart Association (AHA)/Multi-society (MS) Guideline recommendations are intended to provide a strong evidence-based foundation for the treatment of blood cholesterol for the primary and secondary prevention and treatment of ASCVD in patients of all ages. The document concludes that the addition of statin therapy reduces the risk of ASCVD among high-risk individuals, defined as follows: individuals with clinical ASCVD, with LDL-C >= 190 mg/dL, with diabetes, or individuals with >= 20 percent risk of ASCVD as determined via use of an ASCVD risk estimator derived from the Pooled Cohort Equations (Grundy et al., 2019).

One study surveying U.S. cardiology, primary care, and endocrinology practices found that 1 in 4 guideline-eligible patients were not on a statin and less than half were on the recommended statin intensity. Untreated and undertreated patients had significantly higher LDL-C levels than those receiving guideline-directed statin treatment (Navar et al., 2017). In a follow-up study authored by Nanna et al., the same clinics were divided into tertiles based on the percentage of patients with guideline-recommended statin use. The researchers found that patients in the high-tertile clinics were more likely to achieve target LDL-C levels than patients at the low- or mid-tertile clinics, and this held true when patients were stratified by primary and secondary prevention (Nanna et al., 2019a).

Research also indicates that certain populations are far less likely to receive guideline-recommended statin therapy than others. A retrospective study of the National Health and Nutrition Examination Survey found that Black and Hispanic race or ethnicity, low income, lack of health insurance coverage, poor health care access, young age, and female gender are predictors of lower statin utilization (Gu et al., 2018). In particular, there is extensive evidence that women are far less likely than men to be prescribed guideline-recommended statin therapy (Nanna et al., 2019b), despite research showing that female patients with cardiovascular disease derive the same or greater benefit from statin therapy as male patients with cardiovascular disease (Puri et al., 2014).

The Statin Safety Expert Panel that participated in a National Lipid Association (NLA) Statin Safety Task Force meeting in October 2013 reaffirms the general safety of statin therapy. The panel members concluded that for most patients requiring statin therapy, the potential benefits of statin therapy outweigh the potential risks. In general terms, the benefits of statins to prevent non-fatal myocardial infarction, revascularization, stroke, and CVD mortality, far outweigh any potential harm related to the drug (Jacobson, 2014).

Clinical recommendation statement:

This electronic clinical quality measure is intended to align with the 2018 ACC/AHA/MS Guideline on the Management of Blood Cholesterol (Grundy et al., 2019), which indicates the use of statins as the first line of cholesterol-lowering medication therapy to lower the risk of ASCVD among at-risk populations.

Recommendations for Management of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults - Statin Treatment: Secondary Prevention:

  1. In patients who are 75 years of age or younger with clinical ASCVD, high-intensity statin therapy should be initiated or continued with the aim of achieving a 50 percent or greater reduction in LDL-C levels (Class I Recommendation), (Grundy et al., 2019).

  2. In patients with clinical ASCVD in whom high-intensity statin therapy is contraindicated or who experience statin-associated side effects, moderate-intensity statin therapy should be initiated or continued with the aim of achieving a 30 to 49 percent reduction in LDL-C levels (Class I Recommendation), (Grundy et al., 2019).

  3. In patients older than 75 years of age with clinical ASCVD, it is reasonable to initiate moderate- or high-intensity statin therapy after evaluation of the potential for ASCVD risk reduction, adverse effects, and drug–drug interactions, as well as patient frailty and patient preferences (Class IIa Recommendation), (Grundy et al., 2019).

Primary Prevention

  1. In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (>= 4.9 mmol/L), maximally tolerated statin therapy is recommended. (Class I Recommendation), (Grundy et al., 2019).

  2. In adults 40 to 75 years of age with diabetes mellitus, regardless of estimated 10-year ASCVD risk, moderate-intensity statin therapy is indicated (Class I Recommendation), (Grundy et al., 2019).

  3. To facilitate decisions about preventive interventions, it is recommended to screen for traditional ASCVD risk factors and apply the race- and sex-specific Pooled Cohort Equations (PCE) to estimate 10-year ASCVD risk for asymptomatic adults 40 to 75 years of age. The higher the estimated risk, the more likely the patient is to benefit from statin treatment (Grundy et al., 2019).

The US Preventive Services Task Force (USPSTF) concludes with moderate certainty that statin use for the prevention of CVD events and all-cause mortality in adults aged 40 to 75 years with no history of CVD and who have 1 or more of these CVD risk factors and an estimated 10-year CVD event risk of 7.5 percent to less than 10 percent has at least a small net benefit (USPSTF 2022).

Statin Safety and Statin-Associated Side Effects A clinician–patient risk discussion is recommended before initiation of statin therapy to review net clinical benefit, weighing the potential for ASCVD risk reduction against the potential for statin-associated side effects, statin–drug interactions, and safety, while emphasizing that side effects can be addressed successfully (Class I Recommendation), (Grundy et al., 2019).

Guidance (Usage): Initial Population Guidance: The initial population covers four distinct populations. Use the following process to prevent counting patients more than once. Initial Population 1: All patients who were previously diagnosed with or currently have a diagnosis of clinical ASCVD, including an ASCVD procedure before the end of the measurement period. - If YES, meets Initial Population 1 risk category. - If NO, screen for next risk category. Initial Population 2: Patients aged 20 to 75 years at the beginning of the measurement period who have ever had a laboratory test result of LDL-C >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia. - If YES, meets Initial Population 2 risk category. - If NO, screen for next risk category. Initial Population 3: Patients aged 40 to 75 years at the beginning of the measurement period with an active diagnosis of Type 1 or Type 2 diabetes at any time during the measurement period. - If YES, meets Initial Population 3 risk category. - If NO, screen for next risk category. Initial Population 4: Patients aged 40 to 75 at the beginning of the measurement period with a 10-year ASCVD risk score of >= 20 percent during the measurement period. - If YES, meets Initial Population 4 risk category. - If NO, patient does NOT meet Initial Population criteria and is NOT eligible for measure inclusion. Initial Population Guidance for Encounter: In order for the patient to be included in the Initial Population, the patient must have ONE initial population-eligible visit, defined as follows: outpatient visit, initial or established office visit, face-to-face interaction, preventive care services, or annual wellness visit. LDL-C Laboratory test result options: The measure can be reported for all patients with a documented LDL-C level recorded as follows: To meet Initial Population 1: There is no LDL-C result required. To meet Initial Population 2: If a patient has ANY previous laboratory result of LDL-C >= 190 mg/dL, report the highest value >= 190 mg/dL. To meet Initial Population 3: There is no LDL-C result required. To meet Initial Population 4: There is no LDL-C result required. The 10-year ASCVD risk assessment options: The 10-year ASCVD risk score is calculated using the Pooled Cohort Equations: 1) the 2013 ACC/AHA ASCVD Risk Estimator (maps to LOINC Code 79423-0) OR 2) the ACC Risk Estimator Plus (maps to LOINC Code 99055-6). If your EHR does not have either of these risk calculators, we recommend that you use the on-line versions. The 10-year ASCVD risk score (quantitative result, i.e., result.value, "%") must be documented in a structured field. The 10-year ASCVD risk assessment must be performed during the measurement period. Numerator instructions and guidance: - Current statin therapy use must be documented in the patient's current medication list or ordered during the measurement period. - ONLY statin therapy meets the measure Numerator criteria (NOT other cholesterol lowering medications). - Prescription or order does NOT need to be linked to an encounter or visit; it may be called to the pharmacy. - Statin medication "samples" provided to patients can be documented as "current statin therapy" if documented in the medication list in health/medical record. - Patients who meet the denominator criteria for inclusion, but are not prescribed or using statin therapy, will NOT meet performance for this measure unless they have an allowable denominator exception. Patients with an allowable denominator exception should be removed from the denominator of the measure and reported as a valid exception. - There is only one performance rate calculated for this measure: the weighted average of the four populations. - Adherence to statin therapy is not calculated in this measure. - It may not be appropriate to prescribe statin therapy for some patients (see exceptions and exclusions for the complete list). Intensity of statin therapy in primary and secondary prevention: The expert panel of the 2018 ACC/AHA/MS Guidelines (Grundy et al., 2019) defines recommended intensity of statin therapy on the basis of the average expected LDL-C response to specific statin and dose. Although intensity of statin therapy is important in managing cholesterol, this measure assesses prescription of ANY statin therapy, irrespective of intensity. Assessment of appropriate intensity and dosage documentation added too much complexity to allow inclusion of statin therapy intensity in the measure at this time. Lifestyle modification coaching: A healthy lifestyle is important for the prevention of cardiovascular disease. However, lifestyle modification monitoring and documentation added too much complexity to allow its inclusion in the measure at this time. Millimoles per liter (mmol/L) should be converted to milligrams per deciliter (mg/dL) for reporting this measure. This eCQM is a patient-based measure. This FHIR-based measure has been derived from the QDM-based measure: CMS 347v8. Please refer to the HL7 QI-Core Implementation Guide (https://hl7.org/fhir/us/qicore/STU4.1.1/) for more information on QI-Core and mapping recommendations from QDM to QI-Core 4.1.1 (https://hl7.org/fhir/us/qicore/STU4.1.1/qdm-to-qicore.html).
Population Criteria:
64ef76a356d636294b157b96
Initial Population: All patients who were previously diagnosed with or currently have a diagnosis of clinical ASCVD, including an ASCVD procedure.
Denominator: Equals Initial Population
Denominator Exclusion: Patients who are breastfeeding at any time during the measurement period. Patients who have a diagnosis of rhabdomyolysis at any time during the measurement period.
Numerator: Patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period
Denominator Exception: Patients with statin-associated muscle symptoms or an allergy to statin medication. Patients who are receiving palliative or hospice care. Patients with active liver disease or hepatic disease or insufficiency. Patients with end-stage renal disease (ESRD). Patients with documentation of a medical reason for not being prescribed statin therapy.
64ef76a356d636294b157b97
Initial Population: Patients aged 20 to 75 years at the beginning of the measurement period who have ever had a laboratory result of LDL-C >=190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia.
Denominator: Equals Initial Population
Denominator Exclusion: Patients who are breastfeeding at any time during the measurement period. Patients who have a diagnosis of rhabdomyolysis at any time during the measurement period.
Numerator: Patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period
Denominator Exception: Patients with statin-associated muscle symptoms or an allergy to statin medication. Patients who are receiving palliative or hospice care. Patients with active liver disease or hepatic disease or insufficiency. Patients with end-stage renal disease (ESRD). Patients with documentation of a medical reason for not being prescribed statin therapy.
64ef76a356d636294b157b98
Initial Population: Patients aged 40 to 75 years at the beginning of the measurement period with Type 1 or Type 2 diabetes.
Denominator: Equals Initial Population
Denominator Exclusion: Patients who are breastfeeding at any time during the measurement period. Patients who have a diagnosis of rhabdomyolysis at any time during the measurement period.
Numerator: Patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period
Denominator Exception: Patients with statin-associated muscle symptoms or an allergy to statin medication. Patients who are receiving palliative or hospice care. Patients with active liver disease or hepatic disease or insufficiency. Patients with end-stage renal disease (ESRD). Patients with documentation of a medical reason for not being prescribed statin therapy.
64ef76a356d636294b157b99
Initial Population: Population 4: Patients aged 40 to 75 at the beginning of the measurement period with a 10-year ASCVD risk score (i.e., 2013 ACC/AHA ASCVD Risk Estimator or the ACC Risk Estimator Plus) of >= 20 percent during the measurement period.
Denominator: Equals Initial Population
Denominator Exclusion: Patients who are breastfeeding at any time during the measurement period. Patients who have a diagnosis of rhabdomyolysis at any time during the measurement period.
Numerator: Patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period
Denominator Exception: Patients with statin-associated muscle symptoms or an allergy to statin medication. Patients who are receiving palliative or hospice care. Patients with active liver disease or hepatic disease or insufficiency. Patients with end-stage renal disease (ESRD). Patients with documentation of a medical reason for not being prescribed statin therapy.
Supplemental Data Elements:

SDE Ethnicity

SDE Payer

SDE Race

SDE Sex

Supplemental Data Guidance : For every patient evaluated by this measure also identify payer, race, ethnicity and sex; SDE Ethnicity SDE Payer SDE Race SDE Sex
Libraries:
StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR
Terminology and Other Dependencies:
  • Library/QICoreCommon|2.1.000
  • Library/FHIRHelpers|4.4.000
  • Library/SupplementalDataElements|3.5.000
  • Library/Hospice|6.12.000
  • Library/Status|1.8.000
  • Library/PalliativeCare|1.11.000
  • Condition Category Codes
  • US Core Condition Category Extension Codes
  • International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)
  • Logical Observation Identifiers, Names and Codes (LOINC)
  • AdministrativeGender
  • AllergyIntolerance Clinical Status Codes
  • SNOMED CT (all versions)
  • Observation Category Codes
  • Myocardial Infarction
  • Cerebrovascular Disease, Stroke, TIA
  • Atherosclerosis and Peripheral Arterial Disease
  • Ischemic Heart Disease or Other Related Diagnoses
  • Stable and Unstable Angina
  • PCI
  • CABG Surgeries
  • Carotid Intervention
  • CABG, PCI Procedure
  • Annual Wellness Visit
  • Office Visit
  • Outpatient Consultation
  • Outpatient Encounters for Preventive Care
  • Preventive Care Services - Established Office Visit, 18 and Up
  • Preventive Care Services-Individual Counseling
  • Preventive Care Services-Initial Office Visit, 18 and Up
  • Preventive Care Services - Other
  • LDL Cholesterol
  • Hypercholesterolemia
  • Diabetes
  • Low Intensity Statin Therapy
  • Moderate Intensity Statin Therapy
  • High Intensity Statin Therapy
  • Payer
  • Breastfeeding
  • Rhabdomyolysis
  • Statin Allergen
  • Encounter Inpatient
  • http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1003
  • Hospice Care Ambulatory
  • http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1165
  • http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1167
  • http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1090
  • http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1135
  • Hepatitis A
  • Hepatitis B
  • Liver Disease
  • http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.85
  • End Stage Renal Disease
  • Medical Reason
  • Parameters:
    name use min max type
    Measurement Period In 0 1 Period
    Initial Population 1 Out 0 1 boolean
    Initial Population 2 Out 0 1 boolean
    SDE Race Out 0 1 Resource
    Initial Population 3 Out 0 1 boolean
    Initial Population 4 Out 0 1 boolean
    SDE Sex Out 0 1 Coding
    Denominator 3 Out 0 1 boolean
    Numerator Out 0 1 boolean
    Denominator 2 Out 0 1 boolean
    Denominator 4 Out 0 1 boolean
    SDE Payer Out 0 * Resource
    SDE Ethnicity Out 0 1 Resource
    Denominator Exclusions Out 0 1 boolean
    Denominator 1 Out 0 1 boolean
    Denominator Exceptions Out 0 1 boolean
    DataRequirements:
    Resource Type Resource Elements Valueset Name Valueset
    Condition(QICoreCondition) code Myocardial Infarction Myocardial Infarction
    Condition(QICoreCondition) code Cerebrovascular Disease Stroke or TIA Cerebrovascular Disease, Stroke, TIA
    Condition(QICoreCondition) code Atherosclerosis and Peripheral Arterial Disease Atherosclerosis and Peripheral Arterial Disease
    Condition(QICoreCondition) code Ischemic Heart Disease or Other Related Diagnoses Ischemic Heart Disease or Other Related Diagnoses
    Condition(QICoreCondition) code Stable and Unstable Angina Stable and Unstable Angina
    Condition(QICoreCondition) code
    Condition(QICoreCondition) code Familial Hypercholesterolemia Hypercholesterolemia
    Condition(QICoreCondition) code Diabetes Diabetes
    Condition(QICoreCondition) code Breastfeeding Breastfeeding
    Condition(QICoreCondition) code Rhabdomyolysis Rhabdomyolysis
    Condition(QICoreCondition) code Hospice Diagnosis http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1165
    Condition(QICoreCondition) code Palliative Care Diagnosis http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1167
    Condition(QICoreCondition) code Hepatitis A Hepatitis A
    Condition(QICoreCondition) code Hepatitis B Hepatitis B
    Condition(QICoreCondition) code Liver Disease Liver Disease
    Condition(QICoreCondition) code Statin Associated Muscle Symptoms http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.85
    Condition(QICoreCondition) code End Stage Renal Disease End Stage Renal Disease
    Procedure(QICoreProcedure) code performed status status.value PCI PCI
    Procedure(QICoreProcedure) code performed status status.value CABG Surgeries CABG Surgeries
    Procedure(QICoreProcedure) code performed status status.value Carotid Intervention Carotid Intervention
    Procedure(QICoreProcedure) code performed status status.value CABG or PCI Procedure CABG, PCI Procedure
    Procedure(QICoreProcedure) code performed status status.value Hospice Care Ambulatory Hospice Care Ambulatory
    Procedure(QICoreProcedure) code performed status status.value Palliative Care Intervention http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1135
    Encounter(QICoreEncounter) type period status status.value Annual Wellness Visit Annual Wellness Visit
    Encounter(QICoreEncounter) type period status status.value Office Visit Office Visit
    Encounter(QICoreEncounter) type period status status.value Outpatient Consultation Outpatient Consultation
    Encounter(QICoreEncounter) type period status status.value Outpatient Encounters for Preventive Care Outpatient Encounters for Preventive Care
    Encounter(QICoreEncounter) type period status status.value Preventive Care Services Established Office Visit, 18 and Up Preventive Care Services - Established Office Visit, 18 and Up
    Encounter(QICoreEncounter) type period status status.value Preventive Care Services Individual Counseling Preventive Care Services-Individual Counseling
    Encounter(QICoreEncounter) type period status status.value Preventive Care Services Initial Office Visit, 18 and Up Preventive Care Services-Initial Office Visit, 18 and Up
    Encounter(QICoreEncounter) type period status status.value Preventive Care Services Other Preventive Care Services - Other
    Encounter(QICoreEncounter) type hospitalization hospitalization.dischargeDisposition period status status.value Encounter Inpatient Encounter Inpatient
    Encounter(QICoreEncounter) type period status status.value Hospice Encounter http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1003
    Encounter(QICoreEncounter) type period status status.value Palliative Care Encounter http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1090
    Patient(QICorePatient) race ethnicity
    Observation(QICoreObservation) code value effective status status.value category LDL Cholesterol LDL Cholesterol
    Observation(QICoreObservation) code value effective status status.value category
    Observation(QICoreObservation) code value effective status status.value category
    Observation(QICoreObservation) code value effective status status.value category
    Observation(QICoreObservation) code effective value status status.value category
    Medication(QICoreMedication) id
    Medication(QICoreMedication) id
    Medication(QICoreMedication) id
    MedicationRequest(QICoreMedicationRequest) medication.reference status status.value intent intent.value authoredOn authoredOn.value dosageInstruction
    MedicationRequest(QICoreMedicationRequest) medication status status.value intent intent.value authoredOn authoredOn.value dosageInstruction Low Intensity Statin Therapy Low Intensity Statin Therapy
    MedicationRequest(QICoreMedicationRequest) medication status status.value intent intent.value authoredOn authoredOn.value dosageInstruction Moderate Intensity Statin Therapy Moderate Intensity Statin Therapy
    MedicationRequest(QICoreMedicationRequest) medication status status.value intent intent.value authoredOn authoredOn.value dosageInstruction High Intensity Statin Therapy High Intensity Statin Therapy
    Coverage(QICoreCoverage) type period Payer Type Payer
    AllergyIntolerance(QICoreAllergyIntolerance) code onset clinicalStatus Statin Allergen Statin Allergen
    ServiceRequest(QICoreServiceRequest) code authoredOn authoredOn.value status status.value intent intent.value Hospice Care Ambulatory Hospice Care Ambulatory
    AdverseEvent(QICoreAdverseEvent) event recordedDate recordedDate.value Statin Allergen Statin Allergen
    MedicationRequest(QICoreMedicationNotRequested) medication authoredOn authoredOn.value status status.value reasonCode Low Intensity Statin Therapy Low Intensity Statin Therapy
    MedicationRequest(QICoreMedicationNotRequested) medication authoredOn authoredOn.value status status.value reasonCode Low Intensity Statin Therapy Low Intensity Statin Therapy
    MedicationRequest(QICoreMedicationNotRequested) medication authoredOn authoredOn.value status status.value reasonCode Moderate Intensity Statin Therapy Moderate Intensity Statin Therapy
    MedicationRequest(QICoreMedicationNotRequested) medication authoredOn authoredOn.value status status.value reasonCode Moderate Intensity Statin Therapy Moderate Intensity Statin Therapy
    MedicationRequest(QICoreMedicationNotRequested) medication authoredOn authoredOn.value status status.value reasonCode High Intensity Statin Therapy High Intensity Statin Therapy
    MedicationRequest(QICoreMedicationNotRequested) medication authoredOn authoredOn.value status status.value reasonCode High Intensity Statin Therapy High Intensity Statin Therapy
    Direct Reference Codes:
    display code system
    Problem List Item problem-list-item http://terminology.hl7.org/CodeSystem/condition-category
    Health Concern health-concern http://hl7.org/fhir/us/core/CodeSystem/condition-category
    Subsequent non-ST elevation (NSTEMI) myocardial infarction I22.2 http://hl7.org/fhir/sid/icd-10-cm
    Cardiovascular disease 10Y risk [Likelihood] 99055-6 http://loinc.org
    Cardiovascular disease 10Y risk [Likelihood] ACC-AHA Pooled Cohort by Goff 2013 79423-0 http://loinc.org
    Male M http://hl7.org/fhir/administrative-gender
    Female F http://hl7.org/fhir/administrative-gender
    Active active http://terminology.hl7.org/CodeSystem/allergyintolerance-clinical
    Discharge to home for hospice care (procedure) 428361000124107 http://snomed.info/sct
    Discharge to healthcare facility for hospice care (procedure) 428371000124100 http://snomed.info/sct
    survey survey http://terminology.hl7.org/CodeSystem/observation-category
    Yes (qualifier value) 373066001 http://snomed.info/sct
    Hospice care [Minimum Data Set] 45755-6 http://loinc.org
    Functional Assessment of Chronic Illness Therapy - Palliative Care Questionnaire (FACIT-Pal) 71007-9 http://loinc.org
    Logic Definitions:
    Group Scoring Population Criteria Expression
    64ef76a356d636294b157b96 Group scoring: proportion Measure scoring:

    Proportion

    Type:

    Process

    Rate Aggregation: This measure is intended to have one reporting rate, which aggregates the following populations into a single performance rate for reporting purposes: Population 1: All patients who were previously diagnosed with or currently have a diagnosis of clinical ASCVD, including an ASCVD procedure. Population 2: Patients aged 20 to 75 years at the beginning of the measurement period who have ever had a laboratory result of LDL-C >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia. Population 3: Patients aged 40 to 75 years at the beginning of the measurement period with an active diagnosis of Type 1 or Type 2 diabetes at any time during the measurement period. Population 4: Patients aged 40 to 75 at the beginning of the measurement period with a 10-year ASCVD risk score of > = 20 percent during the measurement period. For the purposes of this measure, a single performance rate can be calculated as follows: Performance Rate = (Numerator 1 + Numerator 2 + Numerator 3 + Numerator 4)/ [(Denominator 1 - Denominator Exclusions 1- Denominator Exceptions 1) + (Denominator 2 - Denominator Exclusions 2 - Denominator Exceptions 2) + (Denominator 3 - Denominator Exclusions 3 - Denominator Exceptions 3) + (Denominator 4 - Denominator Exclusions 4 - Denominator Exceptions 4)]
    Improvement Notation:

    increase

    Initial Population
    define "Initial Population 1":
      exists ( "ASVCD Diagnosis or Procedure before End of Measurement Period"
          union "Myocardial Infarction before End of Measurement Period"
      )
        and exists "Qualifying Encounter during day of Measurement Period"
    Denominator
    define "Denominator 1":
      "Initial Population 1"
    Denominator Exclusion
    define "Denominator Exclusions":
      exists ( ( [Condition: "Breastfeeding"]
          union [Condition: "Rhabdomyolysis"] ) ExclusionDiagnosis
          where ( ExclusionDiagnosis.isProblemListItem ( )
              or ExclusionDiagnosis.isHealthConcern ( )
          )
            and ExclusionDiagnosis.prevalenceInterval ( ) overlaps day of "Measurement Period"
      )
    Numerator
    define "Numerator":
      exists "Statin Therapy Prescribed Anytime during day of Measurement Period"
    Denominator Exception
    define "Denominator Exceptions":
      "Has Allergy to Statin"
        or Hospice."Has Hospice Services"
        or PalliativeCare."Has Palliative Care in the Measurement Period"
        or "Has Hepatitis or Liver Disease Diagnosis"
        or "Has Statin Associated Muscle Symptoms"
        or "Has ESRD Diagnosis"
        or "Has Adverse Reaction to Statin"
        or "Has Medical Reason for Not Ordering Statin Therapy"
    64ef76a356d636294b157b97 Group scoring: proportion Measure scoring:

    Proportion

    Type:

    Process

    Rate Aggregation: This measure is intended to have one reporting rate, which aggregates the following populations into a single performance rate for reporting purposes: Population 1: All patients who have an active diagnosis of clinical ASCVD or ever had an ASCVD procedure. Population 2: Patients aged >= 20 years at the beginning of the measurement period who have ever had a laboratory result of LDL-C >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia. Population 3: Patients aged 40 to 75 years at the beginning of the measurement period with an active diagnosis of Type 1 or Type 2 diabetes at any time during the measurement period. For the purposes of this measure, a single performance rate can be calculated as follows: Performance Rate = (Numerator 1 + Numerator 2 +Numerator 3)/ [(Denominator 1 - Denominator Exclusions 1- Denominator Exceptions 1) + (Denominator 2 - Denominator Exclusions 2 - Denominator Exceptions 2) +(Denominator 3 - Denominator Exclusions 3 - Denominator Exceptions 3)]
    Improvement Notation:

    increase

    Initial Population
    define "Initial Population 2":
      "Patients Aged 20 to 75 with LDL Cholesterol Result Greater than or Equal to 190 or Hypercholesterolemia without ASCVD"
        and exists "Qualifying Encounter during day of Measurement Period"
    Denominator
    define "Denominator 2":
      "Initial Population 2"
    Denominator Exclusion
    define "Denominator Exclusions":
      exists ( ( [Condition: "Breastfeeding"]
          union [Condition: "Rhabdomyolysis"] ) ExclusionDiagnosis
          where ( ExclusionDiagnosis.isProblemListItem ( )
              or ExclusionDiagnosis.isHealthConcern ( )
          )
            and ExclusionDiagnosis.prevalenceInterval ( ) overlaps day of "Measurement Period"
      )
    Numerator
    define "Numerator":
      exists "Statin Therapy Prescribed Anytime during day of Measurement Period"
    Denominator Exception
    define "Denominator Exceptions":
      "Has Allergy to Statin"
        or Hospice."Has Hospice Services"
        or PalliativeCare."Has Palliative Care in the Measurement Period"
        or "Has Hepatitis or Liver Disease Diagnosis"
        or "Has Statin Associated Muscle Symptoms"
        or "Has ESRD Diagnosis"
        or "Has Adverse Reaction to Statin"
        or "Has Medical Reason for Not Ordering Statin Therapy"
    64ef76a356d636294b157b98 Group scoring: proportion Measure scoring:

    Proportion

    Type:

    Process

    Rate Aggregation: This measure is intended to have one reporting rate, which aggregates the following populations into a single performance rate for reporting purposes: Population 1: All patients who have an active diagnosis of clinical ASCVD or ever had an ASCVD procedure. Population 2: Patients aged >= 20 years at the beginning of the measurement period who have ever had a laboratory result of LDL-C >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia. Population 3: Patients aged 40 to 75 years at the beginning of the measurement period with an active diagnosis of Type 1 or Type 2 diabetes at any time during the measurement period. For the purposes of this measure, a single performance rate can be calculated as follows: Performance Rate = (Numerator 1 + Numerator 2 +Numerator 3)/ [(Denominator 1 - Denominator Exclusions 1- Denominator Exceptions 1) + (Denominator 2 - Denominator Exclusions 2 - Denominator Exceptions 2) +(Denominator 3 - Denominator Exclusions 3 - Denominator Exceptions 3)]
    Improvement Notation:

    increase

    Initial Population
    define "Initial Population 3":
      "Patients Aged 40 to 75 Years with Diabetes without ASCVD or LDL Greater than 190 or Hypercholesterolemia"
        and exists "Qualifying Encounter during day of Measurement Period"
    Denominator
    define "Denominator 3":
      "Initial Population 3"
    Denominator Exclusion
    define "Denominator Exclusions":
      exists ( ( [Condition: "Breastfeeding"]
          union [Condition: "Rhabdomyolysis"] ) ExclusionDiagnosis
          where ( ExclusionDiagnosis.isProblemListItem ( )
              or ExclusionDiagnosis.isHealthConcern ( )
          )
            and ExclusionDiagnosis.prevalenceInterval ( ) overlaps day of "Measurement Period"
      )
    Numerator
    define "Numerator":
      exists "Statin Therapy Prescribed Anytime during day of Measurement Period"
    Denominator Exception
    define "Denominator Exceptions":
      "Has Allergy to Statin"
        or Hospice."Has Hospice Services"
        or PalliativeCare."Has Palliative Care in the Measurement Period"
        or "Has Hepatitis or Liver Disease Diagnosis"
        or "Has Statin Associated Muscle Symptoms"
        or "Has ESRD Diagnosis"
        or "Has Adverse Reaction to Statin"
        or "Has Medical Reason for Not Ordering Statin Therapy"
    64ef76a356d636294b157b99 Group scoring: proportion Measure scoring:

    Proportion

    Type:

    Process

    Initial Population
    define "Initial Population 4":
      "Patients Age 40 to 75 Years and have a 10 Year CVD Risk of High without ASCVD and High LDL and Diabetes"
        and exists "Qualifying Encounter during day of Measurement Period"
    Denominator
    define "Denominator 4":
      "Initial Population 4"
    Denominator Exclusion
    define "Denominator Exclusions":
      exists ( ( [Condition: "Breastfeeding"]
          union [Condition: "Rhabdomyolysis"] ) ExclusionDiagnosis
          where ( ExclusionDiagnosis.isProblemListItem ( )
              or ExclusionDiagnosis.isHealthConcern ( )
          )
            and ExclusionDiagnosis.prevalenceInterval ( ) overlaps day of "Measurement Period"
      )
    Numerator
    define "Numerator":
      exists "Statin Therapy Prescribed Anytime during day of Measurement Period"
    Denominator Exception
    define "Denominator Exceptions":
      "Has Allergy to Statin"
        or Hospice."Has Hospice Services"
        or PalliativeCare."Has Palliative Care in the Measurement Period"
        or "Has Hepatitis or Liver Disease Diagnosis"
        or "Has Statin Associated Muscle Symptoms"
        or "Has ESRD Diagnosis"
        or "Has Adverse Reaction to Statin"
        or "Has Medical Reason for Not Ordering Statin Therapy"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR ASVCD Diagnosis or Procedure before End of Measurement Period
    define "ASVCD Diagnosis or Procedure before End of Measurement Period":
      ( ( [Condition: "Myocardial Infarction"]
          union [Condition: "Cerebrovascular Disease Stroke or TIA"]
          union [Condition: "Atherosclerosis and Peripheral Arterial Disease"]
          union [Condition: "Ischemic Heart Disease or Other Related Diagnoses"]
          union [Condition: "Stable and Unstable Angina"] ) ASCVDDiagnosis
          where ( ASCVDDiagnosis.isProblemListItem ( )
              or ASCVDDiagnosis.isHealthConcern ( )
          )
            and ASCVDDiagnosis.prevalenceInterval ( ) starts on or before day of end of "Measurement Period"
      )
        union ( ( [Procedure: "PCI"]
            union [Procedure: "CABG Surgeries"]
            union [Procedure: "Carotid Intervention"]
            union [Procedure: "CABG or PCI Procedure"] ) ASCVDProcedure
            where ASCVDProcedure.performed.toInterval ( ) starts on or before day of end of "Measurement Period"
              and ASCVDProcedure.status = 'completed'
        )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Myocardial Infarction before End of Measurement Period
    define "Myocardial Infarction before End of Measurement Period":
      [Condition: "Subsequent non-ST elevation (NSTEMI) myocardial infarction"] SubsequentMI
        where ( SubsequentMI.isProblemListItem ( )
            or SubsequentMI.isHealthConcern ( )
        )
          and SubsequentMI.prevalenceInterval ( ) starts on or before day of end of "Measurement Period"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Qualifying Encounter during day of Measurement Period
    define "Qualifying Encounter during day of Measurement Period":
      ( [Encounter: "Annual Wellness Visit"]
        union [Encounter: "Office Visit"]
        union [Encounter: "Outpatient Consultation"]
        union [Encounter: "Outpatient Encounters for Preventive Care"]
        union [Encounter: "Preventive Care Services Established Office Visit, 18 and Up"]
        union [Encounter: "Preventive Care Services Individual Counseling"]
        union [Encounter: "Preventive Care Services Initial Office Visit, 18 and Up"]
        union [Encounter: "Preventive Care Services Other"] ) QualifyingEncounter
        where QualifyingEncounter.period during day of "Measurement Period"
          and QualifyingEncounter.status = 'finished'
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Initial Population 1
    define "Initial Population 1":
      exists ( "ASVCD Diagnosis or Procedure before End of Measurement Period"
          union "Myocardial Infarction before End of Measurement Period"
      )
        and exists "Qualifying Encounter during day of Measurement Period"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Patients Aged 20 to 75 at Start of Measurement Period
    define "Patients Aged 20 to 75 at Start of Measurement Period":
      AgeInYearsAt(date from start of "Measurement Period") in Interval[20, 75]
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR LDL Result Greater Than or Equal To 190
    define "LDL Result Greater Than or Equal To 190":
      [Observation: "LDL Cholesterol"] LDL190
        where LDL190.value as Quantity >= 190 'mg/dL'
          and LDL190.effective.toInterval ( ) starts on or before day of end of "Measurement Period"
          and LDL190.status in { 'final', 'amended', 'corrected', 'appended' }
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Hypercholesterolemia Diagnosis
    define "Hypercholesterolemia Diagnosis":
      ( [Condition: "Familial Hypercholesterolemia"] Hypercholesterolemia
          where ( Hypercholesterolemia.isProblemListItem ( )
              or Hypercholesterolemia.isHealthConcern ( )
          )
            and Hypercholesterolemia.prevalenceInterval ( ) starts on or before day of end of "Measurement Period"
      )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Patients Aged 20 to 75 with LDL Cholesterol Result Greater than or Equal to 190 or Hypercholesterolemia without ASCVD
    define "Patients Aged 20 to 75 with LDL Cholesterol Result Greater than or Equal to 190 or Hypercholesterolemia without ASCVD":
      "Patients Aged 20 to 75 at Start of Measurement Period"
        and exists ( "LDL Result Greater Than or Equal To 190"
            union "Hypercholesterolemia Diagnosis"
        )
        and not exists ( "ASVCD Diagnosis or Procedure before End of Measurement Period" )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Initial Population 2
    define "Initial Population 2":
      "Patients Aged 20 to 75 with LDL Cholesterol Result Greater than or Equal to 190 or Hypercholesterolemia without ASCVD"
        and exists "Qualifying Encounter during day of Measurement Period"
    Library Name Name
    SupplementalDataElements SDE Race
    define "SDE Race":
      Patient.race R
        return Tuple {
          codes: R.ombCategory union R.detailed,
          display: R.text
        }
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR SDE Race
    define "SDE Race":
      SDE."SDE Race"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Has Diabetes Diagnosis
    define "Has Diabetes Diagnosis":
      exists ( [Condition: "Diabetes"] Diabetes
          where ( Diabetes.isProblemListItem ( )
              or Diabetes.isHealthConcern ( )
          )
            and Diabetes.prevalenceInterval ( ) overlaps day of "Measurement Period"
      )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Patients Aged 40 to 75 Years with Diabetes without ASCVD or LDL Greater than 190 or Hypercholesterolemia
    define "Patients Aged 40 to 75 Years with Diabetes without ASCVD or LDL Greater than 190 or Hypercholesterolemia":
      AgeInYearsAt(date from start of "Measurement Period") >= 40
        and AgeInYearsAt(date from start of "Measurement Period") <= 75
        and "Has Diabetes Diagnosis"
        and ( not exists "ASVCD Diagnosis or Procedure before End of Measurement Period"
            and not exists "LDL Result Greater Than or Equal To 190"
            and not exists "Hypercholesterolemia Diagnosis"
        )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Initial Population 3
    define "Initial Population 3":
      "Patients Aged 40 to 75 Years with Diabetes without ASCVD or LDL Greater than 190 or Hypercholesterolemia"
        and exists "Qualifying Encounter during day of Measurement Period"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Ten Year CVD Risk is High
    define "Ten Year CVD Risk is High":
      ( exists ( [Observation: "Cardiovascular disease 10Y risk [Likelihood]"]
          union [Observation: "Cardiovascular disease 10Y risk [Likelihood] ACC-AHA Pooled Cohort by Goff 2013"] ) AtRiskCVD
          where AtRiskCVD.value as Quantity >= 20 '%'
            and AtRiskCVD.effective.toInterval ( ) during day of "Measurement Period"
      )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Patients Age 40 to 75 Years and have a 10 Year CVD Risk of High without ASCVD and High LDL and Diabetes
    define "Patients Age 40 to 75 Years and have a 10 Year CVD Risk of High without ASCVD and High LDL and Diabetes":
      AgeInYearsAt(date from start of "Measurement Period") in Interval[40, 75]
        and "Ten Year CVD Risk is High"
        and not ( exists "ASVCD Diagnosis or Procedure before End of Measurement Period"
            or exists "Hypercholesterolemia Diagnosis"
            or exists "LDL Result Greater Than or Equal To 190"
            or "Has Diabetes Diagnosis"
        )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Initial Population 4
    define "Initial Population 4":
      "Patients Age 40 to 75 Years and have a 10 Year CVD Risk of High without ASCVD and High LDL and Diabetes"
        and exists "Qualifying Encounter during day of Measurement Period"
    Library Name Name
    SupplementalDataElements SDE Sex
    define "SDE Sex":
      case
        when Patient.gender = 'male' then "M"
        when Patient.gender = 'female' then "F"
        else null
      end
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR SDE Sex
    define "SDE Sex":
      SDE."SDE Sex"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Denominator 3
    define "Denominator 3":
      "Initial Population 3"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Statin Therapy Prescribed Anytime during day of Measurement Period
    define "Statin Therapy Prescribed Anytime during day of Measurement Period":
      ( [MedicationRequest: "Low Intensity Statin Therapy"]
        union [MedicationRequest: "Moderate Intensity Statin Therapy"]
        union [MedicationRequest: "High Intensity Statin Therapy"] ) StatinPrescribed
        where StatinPrescribed.status in { 'active', 'completed' }
          and StatinPrescribed.intent ~ 'order'
          and ( StatinPrescribed.authoredOn during day of "Measurement Period"
              or exists ( StatinPrescribed.dosageInstruction.timing T
                  where T.repeat.bounds.toInterval ( ) overlaps day of "Measurement Period"
              )
          )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Numerator
    define "Numerator":
      exists "Statin Therapy Prescribed Anytime during day of Measurement Period"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Denominator 2
    define "Denominator 2":
      "Initial Population 2"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Denominator 4
    define "Denominator 4":
      "Initial Population 4"
    Library Name Name
    SupplementalDataElements SDE Payer
    define "SDE Payer":
      [Coverage: type in "Payer Type"] Payer
        return {
          code: Payer.type,
          period: Payer.period
        }
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR SDE Payer
    define "SDE Payer":
      SDE."SDE Payer"
    Library Name Name
    SupplementalDataElements SDE Ethnicity
    define "SDE Ethnicity":
      Patient.ethnicity E
        return Tuple {
          codes: { E.ombCategory } union E.detailed,
          display: E.text
        }
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR SDE Ethnicity
    define "SDE Ethnicity":
      SDE."SDE Ethnicity"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Denominator Exclusions
    define "Denominator Exclusions":
      exists ( ( [Condition: "Breastfeeding"]
          union [Condition: "Rhabdomyolysis"] ) ExclusionDiagnosis
          where ( ExclusionDiagnosis.isProblemListItem ( )
              or ExclusionDiagnosis.isHealthConcern ( )
          )
            and ExclusionDiagnosis.prevalenceInterval ( ) overlaps day of "Measurement Period"
      )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Denominator 1
    define "Denominator 1":
      "Initial Population 1"
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Has Allergy to Statin
    define "Has Allergy to Statin":
      exists ( [AllergyIntolerance: "Statin Allergen"] StatinAllergy
          where StatinAllergy.onset.toInterval ( ) overlaps day of "Measurement Period"
            and StatinAllergy.clinicalStatus ~ QICoreCommon."allergy-active"
      )
    Library Name Name
    Hospice Has Hospice Services
    define "Has Hospice Services":
      exists ((([Encounter: "Encounter Inpatient"]).isEncounterPerformed()) InpatientEncounter
          where (InpatientEncounter.hospitalization.dischargeDisposition ~ "Discharge to home for hospice care (procedure)"
              or InpatientEncounter.hospitalization.dischargeDisposition ~ "Discharge to healthcare facility for hospice care (procedure)"
          )
            and InpatientEncounter.period.toInterval() ends during day of "Measurement Period"
      )
        or exists ((([Encounter: "Hospice Encounter"]).isEncounterPerformed()) HospiceEncounter
            where HospiceEncounter.period.toInterval() overlaps day of "Measurement Period"
        )
        or exists ((([Observation: "Hospice care [Minimum Data Set]"]).isAssessmentPerformed()) HospiceAssessment
            where HospiceAssessment.value ~ "Yes (qualifier value)"
              and HospiceAssessment.effective.toInterval() overlaps day of "Measurement Period"
        )
        or exists ((([ServiceRequest: "Hospice Care Ambulatory"]).isInterventionOrder()) HospiceOrder
            where HospiceOrder.authoredOn.toInterval() during day of "Measurement Period"
            // and HospiceOrder.doNotPerform is not true
            // https://oncprojectracking.healthit.gov/support/browse/CQLIT-447
        )
        or exists ((([Procedure: "Hospice Care Ambulatory"]).isInterventionPerformed()) HospicePerformed
            where HospicePerformed.performed.toInterval() overlaps day of "Measurement Period"
        )
        or exists (([Condition: "Hospice Diagnosis"]) HospiceCareDiagnosis
            where HospiceCareDiagnosis.prevalenceInterval() overlaps day of "Measurement Period"
        )
    Library Name Name
    PalliativeCare Has Palliative Care in the Measurement Period
    define "Has Palliative Care in the Measurement Period":
      exists ((([Observation: "Functional Assessment of Chronic Illness Therapy - Palliative Care Questionnaire (FACIT-Pal)"]).isAssessmentPerformed()) PalliativeAssessment
          where PalliativeAssessment.effective.toInterval() overlaps day of "Measurement Period"
      )
        or exists ([Condition: "Palliative Care Diagnosis"] PalliativeDiagnosis
            where PalliativeDiagnosis.prevalenceInterval() overlaps day of "Measurement Period"
        )
        or exists ((([Encounter: "Palliative Care Encounter"]).isEncounterPerformed()) PalliativeEncounter
            where PalliativeEncounter.period.toInterval() overlaps day of "Measurement Period"
        )
        or exists ((([Procedure: "Palliative Care Intervention"]).isInterventionPerformed()) PalliativeIntervention
            where PalliativeIntervention.performed.toInterval() overlaps day of "Measurement Period"
        )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Has Hepatitis or Liver Disease Diagnosis
    define "Has Hepatitis or Liver Disease Diagnosis":
      exists ( ( [Condition: "Hepatitis A"]
          union [Condition: "Hepatitis B"]
          union [Condition: "Liver Disease"] ) HepatitisLiverDisease
          where ( HepatitisLiverDisease.isProblemListItem ( )
              or HepatitisLiverDisease.isHealthConcern ( )
          )
            and HepatitisLiverDisease.prevalenceInterval ( ) overlaps day of "Measurement Period"
      )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Has Statin Associated Muscle Symptoms
    define "Has Statin Associated Muscle Symptoms":
      exists ( [Condition: "Statin Associated Muscle Symptoms"] StatinMuscleSymptom
          where ( StatinMuscleSymptom.isProblemListItem ( )
              or StatinMuscleSymptom.isHealthConcern ( )
          )
            and StatinMuscleSymptom.prevalenceInterval ( ) overlaps day of "Measurement Period"
      )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Has ESRD Diagnosis
    define "Has ESRD Diagnosis":
      exists ( [Condition: "End Stage Renal Disease"] ESRD
          where ( ESRD.isProblemListItem ( )
              or ESRD.isHealthConcern ( )
          )
            and ESRD.prevalenceInterval ( ) overlaps day of "Measurement Period"
      )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Has Adverse Reaction to Statin
    define "Has Adverse Reaction to Statin":
      exists ( [AdverseEvent: event in "Statin Allergen"] StatinReaction
          where StatinReaction.recordedDate during day of "Measurement Period"
      )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Has Medical Reason for Not Ordering Statin Therapy
    define "Has Medical Reason for Not Ordering Statin Therapy":
      exists ( ( [MedicationNotRequested: "Low Intensity Statin Therapy"]
          union [MedicationNotRequested: "Moderate Intensity Statin Therapy"]
          union [MedicationNotRequested: "High Intensity Statin Therapy"] ) NoStatinTherapyOrdered
          with "Qualifying Encounter during day of Measurement Period" QualifyingEncounter
            such that NoStatinTherapyOrdered.authoredOn during QualifyingEncounter.period
              and NoStatinTherapyOrdered.status = 'completed'
              and NoStatinTherapyOrdered.reasonCode in "Medical Reason"
      )
    Library Name Name
    StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR Denominator Exceptions
    define "Denominator Exceptions":
      "Has Allergy to Statin"
        or Hospice."Has Hospice Services"
        or PalliativeCare."Has Palliative Care in the Measurement Period"
        or "Has Hepatitis or Liver Disease Diagnosis"
        or "Has Statin Associated Muscle Symptoms"
        or "Has ESRD Diagnosis"
        or "Has Adverse Reaction to Statin"
        or "Has Medical Reason for Not Ordering Statin Therapy"
    Library Name Name
    QICoreCommon isProblemListItem
    /*
    @description: Returns true if the given condition is a problem list item.
    */
    define fluent function isProblemListItem(condition Condition):
      exists (condition.category C
        where C ~ "problem-list-item"
      )
    Library Name Name
    FHIRHelpers ToConcept
    /*
    @description: Converts the given FHIR [CodeableConcept](https://hl7.org/fhir/datatypes.html#CodeableConcept) value to a CQL Concept.
    */
    define function ToConcept(concept FHIR.CodeableConcept):
        if concept is null then
            null
        else
            System.Concept {
                codes: concept.coding C return ToCode(C),
                display: concept.text.value
            }
    Library Name Name
    QICoreCommon isHealthConcern
    /*
    @description: Returns true if the given condition is a health concern
    */
    define fluent function isHealthConcern(condition Condition):
      exists (condition.category C
        where C ~ "health-concern"
      )
    Library Name Name
    QICoreCommon prevalenceInterval
    /*
    @description: Returns an interval representing the normalized prevalence period of a given Condition.
    @comment: Uses the ToInterval and ToAbatementInterval functions to determine the widest potential interval from
    onset to abatement as specified in the given Condition. If the condition is active, or has an abatement date the resulting 
    interval will have a closed ending boundary. Otherwise, the resulting interval will have an open ending boundary.
    */
    define fluent function prevalenceInterval(condition Condition):
    if condition.clinicalStatus ~ "active"
      or condition.clinicalStatus ~ "recurrence"
      or condition.clinicalStatus ~ "relapse" then
      Interval[start of condition.onset.toInterval(), end of condition.abatementInterval()]
    else
        (end of condition.abatementInterval()) abatementDate
        return if abatementDate is null then
          Interval[start of condition.onset.toInterval(), abatementDate)
        else
          Interval[start of condition.onset.toInterval(), abatementDate]
    Library Name Name
    FHIRHelpers ToString
    define function ToString(value uri): value.value
    Library Name Name
    FHIRHelpers ToCode
    /*
    @description: Converts the given FHIR [Coding](https://hl7.org/fhir/datatypes.html#Coding) value to a CQL Code.
    */
    define function ToCode(coding FHIR.Coding):
        if coding is null then
            null
        else
            System.Code {
              code: coding.code.value,
              system: coding.system.value,
              version: coding.version.value,
              display: coding.display.value
            }
    Library Name Name
    Status isEncounterPerformed
    //Encounter, Performed
    //General usage unless required otherwise by measure intent (e.g., follow-up encounters)
    define fluent function isEncounterPerformed(Enc List<Encounter>):
      Enc E
        where E.status in {'finished', 'arrived', 'triaged', 'in-progress', 'onleave'}
    Library Name Name
    QICoreCommon toInterval
    /*
    @description: Normalizes a value that is a choice of timing-valued types to an equivalent interval
    @comment: Normalizes a choice type of DateTime, Quanitty, Interval<DateTime>, or Interval<Quantity> types
    to an equivalent interval. This selection of choice types is a superset of the majority of choice types that are used as possible
    representations for timing-valued elements in QICore, allowing this function to be used across any resource.
    The input can be provided as a DateTime, Quantity, Interval<DateTime> or Interval<Quantity>.
    The intent of this function is to provide a clear and concise mechanism to treat single
    elements that have multiple possible representations as intervals so that logic doesn't have to account
    for the variability. More complex calculations (such as medication request period or dispense period
    calculation) need specific guidance and consideration. That guidance may make use of this function, but
    the focus of this function is on single element calculations where the semantics are unambiguous.
    If the input is a DateTime, the result a DateTime Interval beginning and ending on that DateTime.
    If the input is a Quantity, the quantity is expected to be a calendar-duration interpreted as an Age,
    and the result is a DateTime Interval beginning on the Date the patient turned that age and ending immediately before one year later.
    If the input is a DateTime Interval, the result is the input.
    If the input is a Quantity Interval, the quantities are expected to be calendar-durations interpreted as an Age, and the result
    is a DateTime Interval beginning on the date the patient turned the age given as the start of the quantity interval, and ending
    immediately before one year later than the date the patient turned the age given as the end of the quantity interval.
    If the input is a Timing, an error will be thrown indicating that Timing calculations are not implemented. Any other input will reslt in a null DateTime Interval
    */
    define fluent function toInterval(choice Choice<DateTime, Quantity, Interval<DateTime>, Interval<Quantity>, Timing>):
      case
    	  when choice is DateTime then
        	Interval[choice as DateTime, choice as DateTime]
    		when choice is Interval<DateTime> then
      		choice as Interval<DateTime>
    		when choice is Quantity then
    		  Interval[Patient.birthDate + (choice as Quantity),
    			  Patient.birthDate + (choice as Quantity) + 1 year)
    		when choice is Interval<Quantity> then
    		  Interval[Patient.birthDate + (choice.low as Quantity),
    			  Patient.birthDate + (choice.high as Quantity) + 1 year)
    		when choice is Timing then
          Message(null, true, 'NOT_IMPLEMENTED', 'Error', 'Calculation of an interval from a Timing value is not supported') as Interval<DateTime>
    		else
    			null as Interval<DateTime>
    	end
    Library Name Name
    Status isAssessmentPerformed
    //This library contains functions that are based on QDM 5.6 to QICore 4.1.1 March 2023 (https://github.com/cqframework/CQL-Formatting-and-Usage-Wiki/wiki/Authoring-Patterns---QICore-v4.1.1). The functions may appear similar to some QICoreCommon functions but different in that they have constraints that are relevant for measures authored by NCQA.
    
    //Assessment, Performed
    define fluent function isAssessmentPerformed(Obs List<Observation>):
      Obs O
        where O.status in { 'final', 'amended', 'corrected' }
              and exists ( O.category ObservationCategory
              where ( ObservationCategory ) ~ "survey"
          )
    Library Name Name
    Status isInterventionOrder
    //Intervention, Order: active and completed only    
    define fluent function isInterventionOrder(ServiceRequest List<ServiceRequest>):
      ServiceRequest S
        where S.status in { 'active', 'completed' }
          and S.intent = 'order'
    Library Name Name
    Status isInterventionPerformed
    //Intervention, Performed
    define fluent function isInterventionPerformed(Proc List<Procedure>):
      Proc P
        where P.status ~ 'completed'